Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

related to degree

  • Carrera, M. Rocio Alberro, Ph.D. in Molecular Biology and Neurosciences, Scripps Research 2001 - 2005

authors

  • Carrera, M. Rocio Alberro
  • Trigo, J. M.
  • Wirsching, P.
  • Roberts, Amanda
  • Janda, Kim

publication date

  • August 2005

journal

  • Pharmacology, Biochemistry and Behavior  Journal

abstract

  • The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive. Current protein-based technology offers a new therapeutic venue by which antibodies bind the drug in the blood stream, inactivating its toxic effects. The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose. Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg. GNC92H2 was delivered 30 min before, concomitantly or 3 min after cocaine treatment. Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%. Importantly, GNC92H2 prevented death even post-cocaine injection. The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.

subject areas

  • Animals
  • Antibodies, Monoclonal
  • Behavior, Animal
  • Cocaine
  • Dose-Response Relationship, Drug
  • Drug Overdose
  • Immunotherapy
  • Male
  • Mice
  • Seizures
  • Survival Rate
  • Time Factors
scroll to property group menus

Research

keywords

  • GNC92H2
  • cocaine-induced toxicity
  • immunotherapy
  • mice
  • monoclonal antibody
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0091-3057

Digital Object Identifier (DOI)

  • 10.1016/j.pbb.2005.04.018

PubMed ID

  • 16005948
scroll to property group menus

Additional Document Info

start page

  • 709

end page

  • 714

volume

  • 81

issue

  • 4

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support